Functional Outcomes and Quality of Life in High-risk Prostate Cancer Patients Treated by Robot-assisted Radical Prostatectomy with or Without Adjuvant Treatments.

Continence Erectile dysfunction Functional outcomes High-risk prostate cancer Quality of life Radical prostatectomy Robot-assisted radical prostatectomy Sexual health Urinary symptoms

Journal

European urology oncology
ISSN: 2588-9311
Titre abrégé: Eur Urol Oncol
Pays: Netherlands
ID NLM: 101724904

Informations de publication

Date de publication:
15 May 2024
Historique:
received: 30 01 2024
revised: 26 03 2024
accepted: 23 04 2024
medline: 17 5 2024
pubmed: 17 5 2024
entrez: 16 5 2024
Statut: aheadofprint

Résumé

Robot-assisted laparoscopic prostatectomy (RALP) is used frequently to treat prostate cancer; yet, prospective data on the quality of life and functional outcomes are lacking. To assess the quality of life and functional outcomes after radical prostatectomy in different risk groups with or without adjuvant treatments. The Be-RALP database is a prospective multicentre database that covers 9235 RALP cases from 2009 until 2016. Of these 9235 patients, 2336 high-risk prostate cancer patients were matched with low/intermediate-risk prostate cancer patients. Patients were treated with RALP only or followed by radiotherapy and/or hormone treatment. We used a mixed-model analysis to longitudinally analyse quality of life, urinary function, and erectile function between risk groups with or without additional treatments. Risk group was not significant in predicting quality of life, erectile function, or urinary function after RALP. Postoperative treatment (hormone and/or radiotherapy treatment) was significant in predicting International Index of Erectile Function (IIEF-5), sexual activity, and sexual functioning. Risk group was not linked with clinically relevant declines in functional outcomes after RALP. The observed functional outcomes and quality of life are in favour of considering RALP for high-risk prostate cancer. Postoperative treatment resulted in lower erectile function measures without clinically relevant changes in quality of life and urinary functions. Hormone therapy seems to have the most prominent negative effects on these outcomes. This study investigated the quality of life, and urinary and erectile function in patients with aggressive and less aggressive prostate cancer after surgery only or in combination with hormones or radiation. We found that quality of life recovers completely, while erectile and urinary function recovers only partially after surgery. Aggressiveness of the disease had a minimal effect on the outcomes; yet, postoperative treatments lowered erectile function further.

Sections du résumé

BACKGROUND BACKGROUND
Robot-assisted laparoscopic prostatectomy (RALP) is used frequently to treat prostate cancer; yet, prospective data on the quality of life and functional outcomes are lacking.
OBJECTIVE OBJECTIVE
To assess the quality of life and functional outcomes after radical prostatectomy in different risk groups with or without adjuvant treatments.
DESIGN, SETTING, AND PARTICIPANTS METHODS
The Be-RALP database is a prospective multicentre database that covers 9235 RALP cases from 2009 until 2016. Of these 9235 patients, 2336 high-risk prostate cancer patients were matched with low/intermediate-risk prostate cancer patients.
INTERVENTION METHODS
Patients were treated with RALP only or followed by radiotherapy and/or hormone treatment.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS METHODS
We used a mixed-model analysis to longitudinally analyse quality of life, urinary function, and erectile function between risk groups with or without additional treatments.
RESULTS AND LIMITATIONS CONCLUSIONS
Risk group was not significant in predicting quality of life, erectile function, or urinary function after RALP. Postoperative treatment (hormone and/or radiotherapy treatment) was significant in predicting International Index of Erectile Function (IIEF-5), sexual activity, and sexual functioning.
CONCLUSIONS CONCLUSIONS
Risk group was not linked with clinically relevant declines in functional outcomes after RALP. The observed functional outcomes and quality of life are in favour of considering RALP for high-risk prostate cancer. Postoperative treatment resulted in lower erectile function measures without clinically relevant changes in quality of life and urinary functions. Hormone therapy seems to have the most prominent negative effects on these outcomes.
PATIENT SUMMARY RESULTS
This study investigated the quality of life, and urinary and erectile function in patients with aggressive and less aggressive prostate cancer after surgery only or in combination with hormones or radiation. We found that quality of life recovers completely, while erectile and urinary function recovers only partially after surgery. Aggressiveness of the disease had a minimal effect on the outcomes; yet, postoperative treatments lowered erectile function further.

Identifiants

pubmed: 38755093
pii: S2588-9311(24)00107-X
doi: 10.1016/j.euo.2024.04.018
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Auteurs

Wout Devlies (W)

Department of Urology, KU Leuven, Leuven, Belgium; Department of Development and Regeneration, KU Leuven, Leuven, Belgium. Electronic address: wout.devlies@kuleuven.be.

Geert Silversmit (G)

Belgian Cancer Registry, Brussels, Belgium.

Filip Ameye (F)

Department of Urology, Maria Middelares Hospital, Ghent, Belgium.

Peter Dekuyper (P)

Department of Urology, Maria Middelares Hospital, Ghent, Belgium.

Thierry Quackels (T)

Department of Urology, Université Libre De Bruxelles, Brussels, Belgium.

Thierry Roumeguère (T)

Department of Urology, Université Libre De Bruxelles, Brussels, Belgium.

Ben Van Cleynenbreugel (B)

Department of Urology, KU Leuven, Leuven, Belgium.

Nancy Van Damme (N)

Belgian Cancer Registry, Brussels, Belgium.

Frank Claessens (F)

Laboratory of Molecular Endocrinology, KU Leuven, Leuven, Belgium.

Wouter Everaerts (W)

Department of Urology, KU Leuven, Leuven, Belgium; Department of Cellular and Molecular Medicine, KU Leuven, Belgium.

Steven Joniau (S)

Department of Urology, KU Leuven, Leuven, Belgium; Department of Development and Regeneration, KU Leuven, Leuven, Belgium.

Classifications MeSH